JP2005512946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512946A5 JP2005512946A5 JP2002586931A JP2002586931A JP2005512946A5 JP 2005512946 A5 JP2005512946 A5 JP 2005512946A5 JP 2002586931 A JP2002586931 A JP 2002586931A JP 2002586931 A JP2002586931 A JP 2002586931A JP 2005512946 A5 JP2005512946 A5 JP 2005512946A5
- Authority
- JP
- Japan
- Prior art keywords
- pimecrolimus
- less
- epithelial inflammatory
- epithelial
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 45
- 208000027866 inflammatory disease Diseases 0.000 claims 31
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 24
- 229960005330 pimecrolimus Drugs 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 21
- 230000036765 blood level Effects 0.000 claims 15
- 230000002265 prevention Effects 0.000 claims 14
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 13
- 208000006673 asthma Diseases 0.000 claims 11
- 230000001506 immunosuppresive effect Effects 0.000 claims 10
- 230000009885 systemic effect Effects 0.000 claims 10
- 241000282412 Homo Species 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 7
- 239000003862 glucocorticoid Substances 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 238000003571 reporter gene assay Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000001388 Opportunistic Infections Diseases 0.000 claims 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940113720 aminosalicylate Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28984301P | 2001-05-09 | 2001-05-09 | |
| PCT/US2002/014637 WO2002089796A2 (en) | 2001-05-09 | 2002-05-09 | Methods for selective immunomodulation using pimecrolimus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512946A JP2005512946A (ja) | 2005-05-12 |
| JP2005512946A5 true JP2005512946A5 (enExample) | 2005-12-22 |
Family
ID=23113348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002586931A Pending JP2005512946A (ja) | 2001-05-09 | 2002-05-09 | 選択的免疫調節法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030119797A1 (enExample) |
| EP (1) | EP1389108A2 (enExample) |
| JP (1) | JP2005512946A (enExample) |
| CN (1) | CN1543345A (enExample) |
| AU (1) | AU2002256507A1 (enExample) |
| BR (1) | BR0209474A (enExample) |
| CA (1) | CA2442969A1 (enExample) |
| WO (1) | WO2002089796A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040087527A1 (en) * | 2002-10-31 | 2004-05-06 | Day Brian J. | Methods for treatment of thiol-containing compound deficient conditions |
| US20060035879A1 (en) * | 2002-11-15 | 2006-02-16 | Prescott Margaret F | Organic Compounds |
| AR043504A1 (es) * | 2003-03-17 | 2005-08-03 | Novartis Ag | Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias |
| GB0307865D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| GB0307862D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| GB0307864D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| US8916546B2 (en) | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| EP1673473B1 (en) * | 2003-10-06 | 2011-07-06 | Novartis AG | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
| MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| GB0505539D0 (en) * | 2005-03-17 | 2005-04-27 | Novartis Ag | Organic compounds |
| EP1875915A4 (en) * | 2005-04-28 | 2010-11-17 | Dainippon Sumitomo Pharma Co | THERAPEUTIC AGENT FOR TREATING CHRONIC OBSTRUCTIVE RESPIRATORY DISEASE |
| EP2162125B1 (en) | 2007-06-13 | 2011-10-19 | Jay Pravda | Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease |
| US8809308B2 (en) | 2012-11-09 | 2014-08-19 | Scidose, Llc | Enema composition for treatment of ulcerative colitis having long term stability |
| GB201319792D0 (en) * | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| PL3215127T3 (pl) | 2014-11-07 | 2021-05-17 | Sublimity Therapeutics Limited | Kompozycje zawierające cyklosporynę |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9318144D0 (en) * | 1993-09-01 | 1993-10-20 | Sandoz Ltd | Organic compounds |
| AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| NZ507211A (en) * | 1998-03-26 | 2003-07-25 | Fujisawa Pharmaceutical Co | Sustained release preparations |
| WO2001026605A2 (en) * | 1999-10-11 | 2001-04-19 | Fujisawa Pharmaceutical Co., Ltd. | Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor |
| GB0012383D0 (en) * | 2000-05-22 | 2000-07-12 | Novartis Ag | Organic compounds |
| GB0125443D0 (en) * | 2001-10-23 | 2001-12-12 | Novartis Ag | Organic Compounds |
| GB0200429D0 (en) * | 2002-01-09 | 2002-02-27 | Novartis Ag | Organic compounds |
-
2002
- 2002-05-09 WO PCT/US2002/014637 patent/WO2002089796A2/en not_active Ceased
- 2002-05-09 JP JP2002586931A patent/JP2005512946A/ja active Pending
- 2002-05-09 CA CA002442969A patent/CA2442969A1/en not_active Abandoned
- 2002-05-09 AU AU2002256507A patent/AU2002256507A1/en not_active Abandoned
- 2002-05-09 US US10/142,851 patent/US20030119797A1/en not_active Abandoned
- 2002-05-09 EP EP02725977A patent/EP1389108A2/en not_active Withdrawn
- 2002-05-09 CN CNA028095200A patent/CN1543345A/zh active Pending
- 2002-05-09 BR BR0209474-6A patent/BR0209474A/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005515966A5 (enExample) | ||
| JP2005512946A5 (enExample) | ||
| JP2005510535A5 (enExample) | ||
| JP2002532392A5 (enExample) | ||
| US20250000933A1 (en) | Terlipressin compositions and their methods of use | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| ES2865278T3 (es) | Amantadina para mejorar la marcha en esclerosis múltiple | |
| JP2018203790A (ja) | ハロフジノンの剤形およびその使用 | |
| JP2006518731A5 (enExample) | ||
| JP2004536829A5 (enExample) | ||
| CN103370066A (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| JP2020536121A5 (enExample) | ||
| JP2009545546A (ja) | リウマチ性疾患の遅延放出型グルココルチコイド治療 | |
| CN113546089B (zh) | 1-乙基-3,7-二甲基黄嘌呤在制备治疗肺炎药物中的应用 | |
| KR20150011379A (ko) | 옥시부티닌 투여를 위한 방법 및 조성물 | |
| JP2016505050A5 (enExample) | ||
| CN101932322A (zh) | 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物 | |
| US12005049B2 (en) | Methods of preventing cancer metastasis | |
| JP2022177119A5 (enExample) | ||
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
| CN111419800A (zh) | 用于治疗红斑狼疮的药物制剂及其制备方法 | |
| KR20100124860A (ko) | 독소필린을 포함하는 변형 방출 조성물 | |
| US11648240B2 (en) | Pharmaceutical composition comprising famotidine, lidocaine and melatonin | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| CN104434948B (zh) | 一种抗胰腺癌的药物组合物及其应用 |